N4 Pharma (LON:N4P) Stock Passes Below Fifty Day Moving Average – Time to Sell?

N4 Pharma Plc (LON:N4P) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 0.61 ($0.01) and traded as low as GBX 0.50 ($0.01). N4 Pharma shares last traded at GBX 0.50 ($0.01), with a volume of 2,734 shares.

N4 Pharma Stock Down 4.8 %

The stock has a market cap of £2.15 million, a price-to-earnings ratio of -1.44 and a beta of -0.37. The company has a 50 day simple moving average of GBX 0.61 and a 200 day simple moving average of GBX 0.60.

About N4 Pharma

N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.